Basilea reports solid 2016 results and expects to double product sales in 2017
(Thomson Reuters ONE) -
Basilea Pharmaceutica AG /
Basilea reports solid 2016 results and expects to double product sales in 2017
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Cresemba(®) launched by Basilea in first European countries and marketed
together with Zevtera(®)/Mabelio(®)
* Entered into distribution and license agreements covering more than 40
countries for both Cresemba and Zevtera/Mabelio
* Product sales of CHF 7.1 million in Europe and CHF 7.3 million royalties
received on 2016 Cresemba US sales
* CHF 289 million cash and financial investments at year-end
* Initiation of ceftobiprole clinical phase 3 development program under BARDA
agreement anticipated mid-2017 to support potential future US regulatory
filing
Basel, Switzerland, February 20, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN)
announced its financial results for 2016 today with product sales from
Cresemba(®) (isavuconazole) and Zevtera(®)/Mabelio(®) (ceftobiprole) of CHF 7.1
million in Europe, royalties on US Cresemba sales of CHF 7.3 million, total
revenue of CHF 66.0 million, a year-end cash and financial investment position
of CHF 289.0 million and a reduced operating loss of CHF 43.9 million.
Basilea's CEO Ronald Scott said: "We've launched Cresemba addressing severe
fungal infections in the first European markets and made substantial progress in
the commercialization of both Cresemba and our antibiotic Zevtera/Mabelio. We
are pleased to announce that we achieved sales for the full year of CHF 7.1
million in Europe. The Cresemba launch is also going well in the USA, where our
license partner Astellas Pharma US reported 2016 sales of USD 46 million, on
which we received CHF 7.3 million in royalties."
He continued: "We plan to initiate a ceftobiprole clinical phase 3 development
program under our agreement with BARDA in mid-2017 to support a potential future
US regulatory filing and we continue to make good progress on our oncology
development programs addressing tumor resistance. We were able to expand our
BAL101553 oral phase 1/2a study to include brain cancer patients according to
plan."
Anti-infectives: Cresemba and Zevtera/Mabelio marketed by Basilea in first
European countries with partnerships in place for important additional markets
Basilea is marketing Cresemba and Zevtera/Mabelio in Germany, Italy, the UK,
France and Austria; Zevtera is also marketed in Switzerland. Basilea's licensing
partner Astellas Pharma US markets Cresemba in the United States. In 2016,
Basilea entered into distribution agreements for isavuconazole and ceftobiprole
with Grupo Biotoscana S.L. in nineteen Latin American countries and with
Unimedic Pharma AB for the Nordics. The distribution agreement with Hikma
Pharmaceuticals LLC for the Middle East and North Africa (MENA) region was
extended to include isavuconazole in addition to ceftobiprole. In addition,
Basilea concluded a license agreement with Asahi Kasei Pharma Corporation for
the development and commercialization of isavuconazole in Japan. Basilea's
existing partnerships cover more than forty countries around the world in
addition to the countries that Basilea is directly serving.
The latest guideline issued by the European Conference on Infections in
Leukaemia (ECIL) recommends Cresemba for the first-line treatment of invasive
aspergillosis in leukemia and hematopoietic stem cell transplant patients. The
guideline states that isavuconazole is as effective as voriconazole with a
better safety profile.(1) This recommendation in one of the most relevant
treatment guidelines in Europe underscores the potentially important clinical
role of Cresemba in the treatment of patients with these life-threatening
infections.
Contract with BARDA to support ceftobiprole phase 3 development for US market
Basilea entered into a contract in 2016 with the Biomedical Advanced Research
and Development Authority (BARDA) for the clinical phase 3 development of
ceftobiprole to support a potential regulatory filing in the US, the largest
market value-wise for branded hospital antibiotics. BARDA provides initial
funding of approximately USD 20 million for the preparation of the phase 3
program. The total value of the BARDA contract could reach USD 100 million over
a period of 4.5 years if pre-defined milestones are met. Basilea submitted
clinical study protocols to the US Food and Drug Administration (FDA) for two
phase 3 studies, one in Staphylococcus aureus bacteremia (SAB) and one in acute
bacterial skin and skin structure infections (ABSSSI). Basilea will initiate the
phase 3 clinical development program once it completes the FDA Special Protocol
Assessment (SPA) process.
Two oncology drug candidates in clinical development: tumor checkpoint
controller BAL101553 and panRAF/SRC kinase inhibitor BAL3833
In 2016 Basilea further strengthened its oncology pipeline, the second pillar of
its hospital-focused strategy, by broadening BAL101553's clinical development
program. A separate study arm for patients with glioblastoma was added to the
ongoing phase 1/2a clinical study with oral BAL101553, based data in preclinical
glioblastoma tumor models demonstrating activity of the drug candidate in this
often lethal brain cancer. Potential patient-selection biomarkers have also been
identified and will be assessed in BAL101553-treated glioblastoma patients. In
addition, a further phase 1/2a clinical study was initiated to explore
continuous intravenous infusion.
Dose-escalation in the phase 1 study with orally administered BAL3833 in
patients with solid tumor cancers, including metastatic melanoma, is continuing
with the aim to determine the maximum tolerated dose. Preclinical data on
BAL3833 presented at the American Association for Cancer Research (AACR) annual
meeting showed that the drug candidate has anti-cancer activity in KRAS-driven
in vitro and in vivo tumor models via inhibition of the RAF and SRC family
kinases. This indicates that BAL3833 may also be effective in non-melanoma KRAS-
mutant cancers such as pancreatic, colorectal and non-small-cell lung cancer,
potentially providing a new therapeutic option in these indications.
Focus 2017 on growing product sales and progress in pipeline
Basilea's CEO Ronald Scott stated: "In 2017, we expect to further grow our
product sales as we continue to execute on our commercialization and partnering
strategy. We anticipate seeing initial contributions from our current
distributors as their first marketing authorizations are granted. We are also
working towards further agreements with potential partners to cover remaining
commercially relevant markets including Asia Pacific, Russia/CIS, and certain
European countries. In addition, we anticipate that Swissmedic will complete its
review of our isavuconazole marketing authorization application in 2017."
He added: "An important goal for us this year is to finalize the Special
Protocol Assessment process with the US FDA in order to start the clinical phase
3 program for ceftobiprole under our BARDA contract. Our initial focus will be
on skin and bloodstream infections, two areas of high medical need."
Ceftobiprole will have a total of ten years of market exclusivity in the US from
potential approval based on its Qualified Infectious Disease Product designation
granted by the FDA. Upon successful completion of the studies, the phase 3 data
could be used to support supplemental marketing authorization applications for
ceftobiprole in Europe and other territories, potentially resulting in label
extensions for ceftobiprole.
In 2017, Basilea will further advance the clinical development of its oncology
drug candidates and expects to complete dose-escalation in BAL101553's phase
1/2a studies and BAL 3833's phase 1 study.
Key figures
+----------------------------------------------+---------+---------+
| (In CHF million, except per share data) | 2016 | 2015 |
+----------------------------------------------+---------+---------+
| Product revenue | 7.1 | - |
+----------------------------------------------+---------+---------+
| Contract revenue | 57.7 | 51.2 |
+----------------------------------------------+---------+---------+
| Revenue from R&D services | 0.2 | 0.5 |
+----------------------------------------------+---------+---------+
| Other revenue | 0.9 | 1.2 |
+----------------------------------------------+---------+---------+
| Total operating income | 66.0 | 52.8 |
+----------------------------------------------+---------+---------+
| Costs of products sold | (5.3) | - |
+----------------------------------------------+---------+---------+
| Research & development expenses, net | (48.4) | (60.1) |
+----------------------------------------------+---------+---------+
| Selling, general & administration expenses | (56.1) | (54.2) |
+----------------------------------------------+---------+---------+
| Total operating expenses | (109.9) | (114.3) |
+----------------------------------------------+---------+---------+
| Operating loss | (43.9) | (61.5) |
+----------------------------------------------+---------+---------+
| Net loss | (51.3) | (61.6) |
+----------------------------------------------+---------+---------+
| Net cash (used in) operating activities | (75.0) | (67.8) |
+----------------------------------------------+---------+---------+
| Cash and financial investments | 289.0 | 364.7 |
+----------------------------------------------+---------+---------+
| Basic and diluted loss per share, in CHF | (5.07) | (6.09) |
+----------------------------------------------+---------+---------+
Notes: Consolidated figures in conformity with US GAAP; rounding was
consistently applied.
The consolidated financial statements of Basilea Pharmaceutica Ltd. for the
financial year 2016 can be found on the company's website at
http://annualreport.basilea.com.
Financial summary
Full-year product revenue 2016 amounted to CHF 7.1 million (2015: none).
Contract revenue 2016 amounted to CHF 57.7 million (2015: CHF 51.2 million),
including CHF 37.7 million (2015: CHF 37.6 million) related to the global
agreement for Toctino(®) and CHF 19.3 million (2015: CHF 13.6 million) related
to the license agreement with Astellas for isavuconazole. Total operating income
in 2016 including sales amounted to CHF 66.0 million (2015: CHF 52.8 million).
Research and development net expenses in 2016 amounted to CHF 48.4 million
(2015: CHF 60.1 million) and were mainly related to activities for the phase
1/2a development of oncology drug candidate BAL101533, phase 1 clinical
development of oncology drug candidate BAL3833, costs for the pediatric program
for ceftobiprole and activities related to isavuconazole. The decrease of CHF
11.7 million as compared to 2015 is mainly due to 2015 isavuconazole pre-launch
activities.
Selling, general and administration expenses in 2016 amounted to
CHF 56.1 million (2015: CHF 54.2 million), and included costs related to the
commercialization of Cresemba and Zevtera/Mabelio and stock-based compensation
of CHF 4.2 million (2015: CHF 4.6 million).
In 2016, the operating loss was reduced by 29% to CHF 43.9 million from
CHF 61.5 million in 2015 and net loss 2016 was reduced to CHF 51.3 million
(2015: CHF 61.6 million), resulting in a lower basic and diluted loss per share
of CHF 5.07 (2015: CHF 6.09).
The net cash used for operating activities in 2016 amounted to CHF 75.0 million
as compared to CHF 67.8 million in 2015. The increase in comparison to 2015 is
mainly due to the milestone payment from Astellas in 2015 upon approval of
isavuconazole in the US, which reduced the net cash used in the previous period.
Combined cash and financial investments amounted to CHF 289.0 million as of
December 31, 2016, compared to CHF 364.7 million as of December 31, 2015.
Financial outlook
Basilea continues to focus on growing sales of its two marketed products while
at the same time advancing its clinical development pipeline. Basilea
anticipates total annual product sales of approximately CHF 15 million in 2017,
a more than 100% increase over 2016, and a participation in US sales through
royalties of approximately CHF 14 million. Total operating expenses after
anticipated BARDA reimbursements for 2017 are estimated at approximately CHF 10
million on average per month with an operating loss of approximately CHF 3
million on average per month.
Portfolio status
Cresemba (isavuconazole) - an i.v. and oral azole antifungal for the treatment
of invasive mold infections
Isavuconazole is an i.v. and oral azole antifungal and the active agent of the
prodrug isavuconazonium sulfate. It is approved in the United States for
patients 18 years of age and older in the treatment of invasive aspergillosis
and invasive mucormycosis.(2) In Europe, isavuconazole received marketing
authorization for the treatment of adult patients with invasive aspergillosis
and for the treatment of adult patients with mucormycosis for whom amphotericin
B is inappropriate.(3) The European marketing authorization is valid in all 28
European Union (EU) member states, as well as in Iceland, Liechtenstein and
Norway. Isavuconazole has orphan drug designation for the approved indications
in Europe and the US. Basilea is marketing isavuconazole as Cresemba in Germany,
Italy, the UK, France and Austria. In the United States Cresemba is marketed by
Basilea's licensee Astellas Pharma US. Outside the US and the EU, isavuconazole
is not approved for commercial use. The European Conference on Infections in
Leukaemia (ECIL) recommends isavuconazole in its current guideline for the
first-line treatment of invasive aspergillosis in leukemia and hematopoietic
stem cell transplant patients.(1)
Zevtera/Mabelio (ceftobiprole) - a broad-spectrum antibiotic from the
cephalosporin class for i.v. administration with bactericidal activity against
certain Gram-positive and Gram-negative bacteria, including methicillin-
resistant Staphylococcus aureus (MRSA) and susceptible Pseudomonas spp.
Ceftobiprole (European trade name Zevtera or Mabelio, depending on the country)
is approved for sale in 13 European countries and several non-European countries
for the treatment of adult patients with community-acquired pneumonia (CAP) and
hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia
(VAP).(4) Basilea is currently marketing the drug in Germany, Italy, the UK,
France, Austria and Switzerland. Ceftobiprole received Qualified Infectious
Disease Product (QIDP) designation from the US FDA for the potential treatment
of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and
skin structure infections (ABSSSI). The drug is not approved in the United
States. In 2016, Basilea entered into a contract with the Biomedical Advanced
Research and Development Authority (BARDA) for the clinical phase 3 development
of ceftobiprole to support a potential regulatory filing in the US. The total
value of the BARDA contract could reach USD 100 million over a period of 4.5
years if pre-defined milestones are met. Initial studies are planned in acute
bacterial skin structure infections (ABSSSI) and Staphylococcus aureus
bacteremia (SAB).
BAL101553 - a tumor checkpoint controller in phase 1/2a clinical testing in
patients with advanced solid tumors including recurrent or progressive
glioblastoma
The small molecule oncology drug candidate BAL101553 (prodrug of BAL27862) is
being developed as a potential therapy for diverse cancers, including tumor
types unresponsive to standard therapeutics. The drug is currently undergoing
clinical phase 1/2a evaluation (oral and continuous infusion) in patients with
advanced solid tumors. In December 2016, the oral study was extended by adding a
separate arm for patients with recurrent or progressive glioblastoma after prior
radiotherapy. The drug candidate has shown evidence of clinical anti-tumor
activity in a phase 1/2a study with weekly 2-hour i.v. infusion, during which
the maximum tolerated dose and the recommended phase 2 dose for this
administration regimen was established.(5)
BAL3833 - a phase 1 oral oncology drug candidate (panRAF/SRC kinase inhibitor)
targeting tumor growth and therapeutic resistance
BAL3833 (also known as CCT3833) is an orally administered small-molecule
panRAF/SRC kinase inhibitor targeting cell proliferation signaling pathways that
are associated with tumor growth and resistance development to current
therapies. It is the lead compound of a series of kinase inhibitors in-licensed
by Basilea in April 2015 under an agreement with The Institute of Cancer
Research, Cancer Research Technology, the Wellcome Trust, and The University of
Manchester. BAL3833 is currently being investigated in a phase 1 study in adult
patients with advanced solid tumors including metastatic melanoma. The compound
originates from the renowned UK cancer research institution, The Institute of
Cancer Research, where it was developed by scientists funded by Cancer Research
UK and the Wellcome Trust.
Conference call
Basilea Pharmaceutica Ltd. invites you to participate in a conference call on
Monday, February 20, 2017, 4 p.m. (CET), during which the company will discuss
today's press release.
Dial-in numbers are:
+41 (0) 58 310 5000 (Europe and RoW)
+1 (1) 631 570 5613 (USA)
+44 (0) 203 059 5862 (UK)
A playback will be available 1 hour after the conference call until Wednesday,
February 22, 2017, 6 p.m. (CET). Participants requesting a digital playback may
dial:
+41 (0) 91 612 4330 (Europe and RoW)
+1 (1) 866 416 2558 (USA)
+44 (0) 207 108 6233 (UK)
and will be asked to enter the ID 19991 followed by the # sign.
Note to shareholders
The shareholders of Basilea Pharmaceutica Ltd. are informed that the Ordinary
General Meeting of Shareholders of Basilea Pharmaceutica Ltd. for the business
year 2016 will take place on Thursday, April 27, 2017 at 2 p.m. at the Radisson
Blu Hotel in Basel, Switzerland. The invitation will be published in the Swiss
Official Gazette of Commerce (Schweizerisches Handelsamtsblatt, SHAB).
Shareholders who are recorded in the share register with voting rights on April
13, 2017 will be entitled to participate and exercise their voting rights.
About Basilea
Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products
that address the medical problem of increasing resistance and non-response to
current treatment options in the therapeutic areas of bacterial infections,
fungal infections and cancer. The company uses the integrated research,
development and commercial operations of its subsidiary Basilea Pharmaceutica
International Ltd. to discover, develop and commercialize innovative
pharmaceutical products to meet the medical needs of patients with serious and
life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in
Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional
information can be found at Basilea's website www.basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance
or achievements of Basilea Pharmaceutica Ltd. to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any forward-
looking statements contained herein as a result of new information, future
events or otherwise.
For further information, please contact:
+----------------------------------------------------+
| Peer Nils Schröder, PhD |
| Head Corporate Communications & Investor Relations |
| +41 61 606 1102 |
| media_relations(at)basilea.com |
| investor_relations(at)basilea.com |
+----------------------------------------------------+
This press release can be downloaded from www.basilea.com.
References
1 F. Tissot et al. ECIL-6 guidelines for the treatment of invasive candidiasis,
aspergillosis and mucormycosis in leukemia and hematopoietic stem cell
transplant patients. Haematologica 2016 (101), published online ahead of print;
www.haematologica.org/content/early/2016/12/20/haematol.2016.152900 [Accessed
February 17, 2017]
2 Cresemba US prescribing information [Accessed: February 17, 2017]
3 European Public Assessment Report (EPAR) Cresemba: http://www.ema.europa.eu
[Accessed: February 17, 2017]
4 UK Summary of Product Characteristics (SPC) Zevtera(®):
http://www.mhra.gov.uk/
[Accessed: February 17, 2017]
5 J. Lopez et al. Phase 1/2a trial of intravenous BAL101553, a novel tumor
checkpoint controller (TCC), in advanced solid tumors. American Society of
Clinical Oncology (ASCO) annual meeting 2016, abstract 2525, poster board #225
Press release (PDF):
http://hugin.info/134390/R/2079896/783150.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Basilea Pharmaceutica AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 20.02.2017 - 07:15 Uhr
Sprache: Deutsch
News-ID 525122
Anzahl Zeichen: 24254
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 339 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Basilea reports solid 2016 results and expects to double product sales in 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
Basilea Pharmaceutica AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
